CA2503746A1 - Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium - Google Patents

Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium Download PDF

Info

Publication number
CA2503746A1
CA2503746A1 CA002503746A CA2503746A CA2503746A1 CA 2503746 A1 CA2503746 A1 CA 2503746A1 CA 002503746 A CA002503746 A CA 002503746A CA 2503746 A CA2503746 A CA 2503746A CA 2503746 A1 CA2503746 A1 CA 2503746A1
Authority
CA
Canada
Prior art keywords
trospium
mammal
pharmaceutically acceptable
acceptable salt
smooth muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002503746A
Other languages
English (en)
Inventor
Gunnar Aberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bridge Pharma Inc
Original Assignee
Bridge Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharma Inc filed Critical Bridge Pharma Inc
Priority to CA002503746A priority Critical patent/CA2503746A1/fr
Publication of CA2503746A1 publication Critical patent/CA2503746A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002503746A 2005-04-05 2005-04-05 Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium Abandoned CA2503746A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002503746A CA2503746A1 (fr) 2005-04-05 2005-04-05 Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002503746A CA2503746A1 (fr) 2005-04-05 2005-04-05 Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium

Publications (1)

Publication Number Publication Date
CA2503746A1 true CA2503746A1 (fr) 2006-10-05

Family

ID=37080900

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002503746A Abandoned CA2503746A1 (fr) 2005-04-05 2005-04-05 Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium

Country Status (1)

Country Link
CA (1) CA2503746A1 (fr)

Similar Documents

Publication Publication Date Title
US6310103B1 (en) S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
DuBuske Second-generation antihistamines: the risk of ventricular arrhythmias
US5532278A (en) Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
KR100390271B1 (ko) (s)-옥시부티닌과(s)-데스에틸옥시부티닌을이용한요실금치료
CA2257121C (fr) Methodes et compositions pour le traitement de l'incontinence urinaire utilisant (s)-oxybutynine
US6123961A (en) Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
EP1286591B1 (fr) Traitement de l'hyperactivite de muscles lisses avec (r)-oxybutynine et (r)-desethyloxybutynine
KR20130043217A (ko) 덱스트로메토르판 및 퀴니딘을 포함하는 신경계 장애의 치료를 위한 약학적 조성물
AU2011235863A1 (en) Methods of improving quality of sleep
US6974820B2 (en) Methods for treating urinary incontinence and other disorders using trospium
US7390816B2 (en) Methods for treating urinary incontinence in patients suffering from memory disorders
AU740504B2 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
US6432446B2 (en) Non-arrhythmogenic metabolite of oxybutynin
US20030027856A1 (en) Tolterodine metabolites
CA2503746A1 (fr) Methodes de traitement de l'incontinence urinaire et d'autres troubles a l'aide de trospium
JP2012176958A (ja) （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
EP1455776A1 (fr) Metabolite non arythmogene de l'oxybutynine
JP2005516992A6 (ja) オキシブチニンの非心律動異常惹起性代謝物
WO1998001125A2 (fr) Isomeres dextrogyres d'oxybutynine et de desethyloxybutynine utilises dans le traitement de l'hyperactivite gastro-intestinale
KR20000022194A (ko) (s)-옥시부티닌과 (s)-데스에틸옥시부티닌을 이용한 요실금치료
CA2550604A1 (fr) Methodes de traitement de troubles des muscles lisses a l'aide de trospium
MXPA99007802A (es) Uso de descarboetociloratadina para la preparacion de un farmaco para el tratamiento de la incontinencia urinaria, malestar causado por el movimiento y vertigo

Legal Events

Date Code Title Description
FZDE Dead